1 Title of your idea

Please provide a short title that accurately reflects the objective(s) of your idea:
As European citizens we need a standard protocol to share personal activity and medical data with personal medical devices and softwares, in order to have a personal data cloud where we can to
give access to personal medical devices/softwares from different brands/companies, to obtain value from the data that devices collect, analyze and upload, or to share our data with this devices or softwares.
As this is not feasible because each company stores their data in their servers or devices, we need be able of download our data from this companies as we can download our personal data from Facebook or Amazon or other companies, but with a standard protocol in order we can share that data with a third party as a file, or upload it to a third company whose service would be the storage and easily sharing of personal medical data, or simply storage it.
Our personal medical data should be in our hands, but we need a project that define what, how, when, and so on, and make this in collaboration with industry to assure an easy adoption, and, most importantly, give some tools to facilitate the way to citizens AND companies (personal medical devices makers, personal medical software developers, cloud services companies.....).

2 Scope

Explain the specific challenges/problems to be addressed by your idea and how these affect relevant stakeholders, taking into account what is already known and/or available in the field:
A lot:
- Regulation about data privacy.
- Regulation about data soberany.
- Protocols to information sharing.
- Data structure to optimize AI processing.
- Databases design for future needs.
- Data storage optimization.
- Cryptography and data security for medical data.
Please indicate which IHI specific objective(s) (SO), as described in the IHI Strategic Research and Innovation Agenda (SRIA), your idea addresses:

["SO1: contribute towards a better understanding of the determinants of health and priority disease areas"
"SO2: integrate fragmented health research and innovation efforts bringing together health industry sectors and other stakeholders, focusing on unmet public health needs, to enable the development of tools, data, platforms, technologies and processes for improved prediction, prevention, interception, diagnosis, treatment and management of diseases, meeting the needs of end-users"
"SO3: demonstrate the feasibility of people-centered, integrate health care solutions"
"SO4: exploit the full potential of digitalisation and data exchange in health care"
"SO5: enable the development of new and improved evaluation methodologies and models for a comprehensive assessment of the added value of innovative and integrated health care solutions"]

Please select the keywords that are most relevant to your idea:

["Non-communicable diseases"
"Cardiovascular diseases"
"Neurodegenerative diseases"
"Rare diseases"
"Prediction"
"Prevention"
"Detection"
"Digital health"
"Health technology"]

In alignment with the IHI specific objective(s) selected above, specify the objectives of your idea:

The very base for digital health is the data. Without a European level initiative to organize the data sharing, we only have a limited impact of all our fragmented, partial initiatives.
3  Expected impacts to be achieved by your idea

Briefly describe the expected impacts to be achieved by your idea, ensuring that they contribute to IHI general and relevant specific objectives, as described in the IHI SRIA:

**Impacts** are wider long-term effects on society (including the environment), the economy and science, enabled by the outcomes of R&I investments. Impacts generally occur sometime after the end of the project, e.g. successful implementation of digital solutions supporting people-centred care.

**IHI general objectives:** 1. contribute towards the creation of an EU-wide health research and innovation ecosystem that facilitates translation of scientific knowledge into innovations, notably by launching at least 30 large-scale, cross-sectoral projects, focussing on health innovations; 2. foster the development of safe, effective, people-centred and cost-effective innovations that respond to strategic unmet public health needs, by exhibiting, in at least 5 examples, the feasibility of integrating health care products or services, with demonstrated suitability for uptake by health care systems. The related projects should address the prevention, diagnosis, treatment and/or management of diseases affecting the EU population, including contribution to ‘Europe’s Beating Cancer Plan’; 3. drive cross-sectoral health innovation for a globally competitive European health industry and contribute to reaching the objectives of the new Industrial Strategy for Europe and the Pharmaceutical Strategy for Europe.

Unleash the raw power of personal medical data at European level to open it to the new era of AI, in order to lead the next revolution or AI applied to the detection, diagnosis, and specially, prevention, of disease.

4  Why should your idea become an IHI call topic?

Explain why collaboration through a cross-sectoral and multidisciplinary public private partnership is needed in particular:

**Why does it require collaboration among several industry sectors (e.g. pharma, vaccines, biotech, medical devices, in vitro diagnostics, radiotherapy, medical imaging health ICT)?**

**Why does it require collaboration between private (industry) and public partners (e.g. academia, healthcare practitioners, patients, regulators)?**

We need medical devices companies (usually very big), software medical companies (usually SME), cloud companies (usually very big), regulators (public servers), medical organizations (usually public servers), patient organizations (at European level), AI companies (from SME to corporations), and of course Academia all of them collaborate to make the next standards and protocols, make the tools and the best practices in order to create a European data space for medical data.

**Why is the contribution of industry needed to achieve the expected impacts?**

**Contribution of industry:** Large companies that are members of the IHI industry partners (i.e. COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe) contribute to the programme, primarily through ‘in-kind’ contributions (e.g. their researchers’ time, laboratories, data, compounds). At least 45% of each project’s total costs have to be in-kind contribution.

Because industry obtain the data through their medical devices.